KCM
AMPH icon

Kennedy Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Kennedy Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-199,603
Closed -$2.32M – 721
2014
Q4 		$2.32M Sell
199,603
-299
-0.1% -$3.26K 0.04% 552
2014
Q3 		$2.33M Sell
199,902
-98
-0% -$1.02K 0.05% 541
2014
Q2 		$2M Buy
+200,000
New +$1.96M 0.04% 554

Other funds holding AMPH

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Kennedy Capital Management's AMPH Position: Q1 2015 in Review

Kennedy Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2015, closing a stake of 199,603 shares — an estimated $2.32M sold.

Kennedy Capital Management first reported a position in AMPH in Q2 2014 and held it in 3 quarters. The position peaked at $2.33M in Q3 2014. 59 funds tracked by Wall St. Rank hold AMPH as of Q1 2015.

  • Kennedy Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Kennedy Capital Management sold 199,603 Amphastar Pharmaceuticals shares in Q1 2015, an estimated $2.32M.
  • Kennedy Capital Management first reported a position in Amphastar Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Kennedy Capital Management's Amphastar Pharmaceuticals position peaked at $2.33M in Q3 2014.
  • 59 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2015.

Based on Kennedy Capital Management's 13F filing for Q1 2015, filed 7 May 2015.